CBS 2019
CBSMD教育中心
中 文

充血性心力衰竭

Abstract

Recommended Article

Phenotypic Refinement of Heart Failure in a National Biobank Facilitates Genetic Discovery sST2 Predicts Outcome in Chronic Heart Failure Beyond NT−proBNP and High-Sensitivity Troponin T 2018 ACC/AHA/HRS Guideline on the Evaluation and Management of Patients With Bradycardia and Cardiac Conduction Delay: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society The Future of Biomarker-Guided Therapy for Heart Failure After the Guiding Evidence-Based Therapy Using Biomarker Intensified Treatment in Heart Failure (GUIDE-IT) Study Phenomapping for Novel Classification of Heart Failure With Preserved Ejection Fraction Effect of Luseogliflozin on Heart Failure With Preserved Ejection Fraction in Patients With Diabetes Mellitus Novel percutaneous interventional therapies in heart failure with preserved ejection fraction: an integrative review Effects of Dapagliflozin on Symptoms, Function and Quality of Life in Patients with Heart Failure and Reduced Ejection Fraction: Results from the DAPA-HF Trial

Original Research2021 Jun 12;cvab202.

JOURNAL:Cardiovasc Res. Article Link

AIM2-driven inflammasome activation in heart failure

Z Onódi, M Ruppert, D Kucsera et al. Keywords: canakinumab; cardiomyopathy; drug repurposing; heart failure; inflammation; probenecid

Full Text PDF